{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:44:43Z","timestamp":1784616283822,"version":"3.55.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-02149-6","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:25:36Z","timestamp":1732080336000},"page":"1143-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Post-transplant IgA nephropathy: a rapidly evolving field of kidney transplant medicine"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasin","family":"Ozbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Guldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2149_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV (2021) IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci 361:176\u2013194","journal-title":"Am J Med Sci"},{"key":"2149_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrneph.2012.58","volume":"8","author":"KN Lai","year":"2012","unstructured":"Lai KN (2012) Pathogenesis of IgA nephropathy. Nat Rev Nephrol 8:275\u2013283","journal-title":"Nat Rev Nephrol"},{"key":"2149_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.kint.2018.02.030","volume":"94","author":"MK Saha","year":"2018","unstructured":"Saha MK, Julian BA, Novak J, Rizk DV (2018) Secondary IgA nephropathy. Kidney Int 94:674\u2013681","journal-title":"Kidney Int"},{"key":"2149_CR4","first-page":"241","volume":"33","author":"FG Silva","year":"1982","unstructured":"Silva FG, Chander P, Pirani CL, Hardy MA (1982) Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33:241\u2013246","journal-title":"Transplantation"},{"key":"2149_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J (2023) Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18:727\u2013738","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 1","key":"2149_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000530341","volume":"147","author":"M Kawabe","year":"2023","unstructured":"Kawabe M, Yamamoto I (2023) Current status and perspectives on recurrent IgA nephropathy after kidney transplantation. Nephron 147(Suppl 1):9\u201313","journal-title":"Nephron"},{"key":"2149_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.00910121","volume":"16","author":"A Uffing","year":"2021","unstructured":"Uffing A, P\u00e9rez-Sa\u00e9z MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue MC, Reindl-Schwaighofer R, Morlock A, Oberbauer R, Buxeda A, Burballa C, Pascual J, von Moos S, Seeger H, La Manna G, Comai G, Bini C, Russo LS, Farouk S, Nissaisorakarn P, Patel H, Agrawal N, Mastroianni-Kirsztajn G, Mansur J, Tedesco-Silva H, Ventura CG, Agena F, David-Neto E, Akalin E, Alani O, Mazzali M, Manfro RC, Bauer AC, Wang AX, Cheng XS, Schold JD, Berger SP, Cravedi P, Riella LV (2021) Recurrence of IgA nephropathy after kidney transplantation in adults. Clin J Am Soc Nephrol 16:1247\u20131255","journal-title":"Clin J Am Soc Nephrol"},{"key":"2149_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1056\/NEJMoa013036","volume":"347","author":"EM Briganti","year":"2002","unstructured":"Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ (2002) Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347:103\u2013109","journal-title":"N Engl J Med"},{"key":"2149_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1681\/ASN.2016020126","volume":"28","author":"MM O'Shaughnessy","year":"2017","unstructured":"O\u2019Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC (2017) Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 28:632\u2013644","journal-title":"J Am Soc Nephrol"},{"key":"2149_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfs472","volume":"28","author":"G Moroni","year":"2013","unstructured":"Moroni G, Longhi S, Quaglini S, Gallelli B, Banfi G, Montagnino G, Messa P (2013) The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant 28:1305\u20131314","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.kint.2017.03.015","volume":"92","author":"PJ Allen","year":"2017","unstructured":"Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, Teixeira-Pinto A, Wong G (2017) Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int 92:461\u2013469","journal-title":"Kidney Int"},{"key":"2149_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","volume":"91","author":"FG Cosio","year":"2017","unstructured":"Cosio FG, Cattran DC (2017) Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int 91:304\u2013314","journal-title":"Kidney Int"},{"key":"2149_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.31486\/toj.21.0083","volume":"21","author":"MMB Mohamed","year":"2021","unstructured":"Mohamed MMB, Wickman TJ, Fogo AB, Velez JCQ (2021) De novo Immunoglobulin A vasculitis following exposure to SARS-CoV-2 immunization. Ochsner J 21:395\u2013401","journal-title":"Ochsner J"},{"key":"2149_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12882-022-02843-2","volume":"23","author":"Y Uchiyama","year":"2022","unstructured":"Uchiyama Y, Fukasawa H, Ishino Y, Nakagami D, Kaneko M, Yasuda H, Furuya R (2022) Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination. BMC Nephrol 23:216","journal-title":"BMC Nephrol"},{"key":"2149_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","volume":"43","author":"L Gesualdo","year":"2021","unstructured":"Gesualdo L, Di Leo V, Coppo R (2021) The mucosal immune system and IgA nephropathy. Semin Immunopathol 43:657\u2013668","journal-title":"Semin Immunopathol"},{"key":"2149_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01874-8","author":"PAS Vaz de Castro","year":"2024","unstructured":"Vaz de Castro PAS, Amaral AA, Almeida MG, Selvaskandan H, Barratt J, Simoes ESAC (2024) Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-023-01874-8","journal-title":"J Nephrol"},{"key":"2149_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","volume":"55","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, Khan A, Marasa M, Zhang JY, Balderes O, Sanna-Cherchi S, Bomback AS, Canetta PA, Appel GB, Radhakrishnan J, Trimarchi H, Sprangers B, Cattran DC, Reich H, Pei Y, Ravani P, Galesic K, Maixnerova D, Tesar V, Stengel B, Metzger M, Canaud G, Maillard N, Berthoux F, Berthelot L, Pillebout E, Monteiro R, Nelson R, Wyatt RJ, Smoyer W, Mahan J, Samhar AA, Hidalgo G, Quiroga A, Weng P, Sreedharan R, Selewski D, Davis K, Kallash M, Vasylyeva TL, Rheault M, Chishti A, Ranch D, Wenderfer SE, Samsonov D, Claes DJ, Akchurin O, Goumenos D, Stangou M, Nagy J, Kovacs T, Fiaccadori E, Amoroso A, Barlassina C, Cusi D, Del Vecchio L, Battaglia GG, Bodria M, Boer E, Bono L, Boscutti G, Caridi G, Lugani F, Ghiggeri G, Coppo R, Peruzzi L, Esposito V, Esposito C, Feriozzi S, Polci R, Frasca G, Galliani M, Garozzo M, Mitrotti A, Gesualdo L, Granata S, Zaza G, Londrino F, Magistroni R, Pisani I, Magnano A, Marcantoni C, Messa P, Mignani R, Pani A, Ponticelli C, Roccatello D, Salvadori M, Salvi E, Santoro D, Gembillo G, Savoldi S, Spotti D, Zamboli P, Izzi C, Alberici F, Delbarba E, Florczak M, Krata N, Mucha K, P\u0105czek L, Niemczyk S, Moszczuk B, Pa\u0144czyk-Tomaszewska M, Mizerska-Wasiak M, Perkowska-Ptasi\u0144ska A, B\u0105czkowska T, Durlik M, Pawlaczyk K, Sikora P, Zaniew M, Kaminska D, Krajewska M, Kuzmiuk-Glembin I, Heleniak Z, Bullo-Piontecka B, Liberek T, D\u0119bska-Slizien A, Hryszko T, Materna-Kiryluk A, Miklaszewska M, Szczepa\u0144ska M, Dyga K, Machura E, Siniewicz-Luze\u0144czyk K, Pawlak-Bratkowska M, Tkaczyk M, Runowski D, Kwella N, Dro\u017cd\u017c D, Habura I, Kronenberg F, Prikhodina L, van Heel D, Fontaine B, Cotsapas C, Wijmenga C, Franke A, Annese V, Gregersen PK, Parameswaran S, Weirauch M, Kottyan L, Harley JB, Suzuki H, Narita I, Goto S, Lee H, Kim DK, Kim YS, Park JH, Cho B, Choi M, Van Wijk A, Huerta A, Ars E, Ballarin J, Lundberg S, Vogt B, Mani LY, Caliskan Y, Barratt J, Abeygunaratne T, Kalra PA, Gale DP, Panzer U, Rauen T, Floege J, Schlosser P, Ekici AB, Eckardt KU, Chen N, Xie J, Lifton RP, Loos RJF, Kenny EE, Ionita-Laza I, K\u00f6ttgen A, Julian BA, Novak J, Scolari F, Zhang H, Gharavi AG (2023) Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 55:1091\u20131105","journal-title":"Nat Genet"},{"key":"2149_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1432-2277.2009.00966.x","volume":"23","author":"SS Han","year":"2010","unstructured":"Han SS, Huh W, Park SK, Ahn C, Han JS, Kim S, Kim YS (2010) Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy. Transpl Int 23:169\u2013175","journal-title":"Transpl Int"},{"key":"2149_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000506853","volume":"51","author":"LM Rodas","year":"2020","unstructured":"Rodas LM, Ruiz-Ortiz E, Garcia-Herrera A, Pereira A, Blasco M, Ventura-Aguiar P, Vi\u00f1as Gomis O, Egri N, De Sousa E, Palou E, Diekmann F, Poch E, Campistol JM, Quintana LF (2020) IgA nephropathy recurrence after kidney transplantation: role of recipient age and human leukocyte antigen-B mismatch. Am J Nephrol 51:357\u2013365","journal-title":"Am J Nephrol"},{"key":"2149_CR20","first-page":"227","volume":"13","author":"S Ahn","year":"2015","unstructured":"Ahn S, Min SI, Min SK, Ha IS, Kang HG, Kim YS, Kim SJ, Hao J (2015) Different recurrence rates between pediatric and adult renal transplant for immunoglobulin A nephropathy: predictors of posttransplant recurrence. Exp Clin Transplant 13:227\u2013232","journal-title":"Exp Clin Transplant"},{"key":"2149_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.transproceed.2019.12.008","volume":"52","author":"JM Cazorla-L\u00f3pez","year":"2020","unstructured":"Cazorla-L\u00f3pez JM, Wu J, Villanego-Fern\u00e1ndez F, Naranjo-Mu\u00f1oz J, Vigara-S\u00e1nchez LA, Garc\u00eda-Garc\u00eda-Doncel A, Orellana-Ch\u00e1vez C, Moreno-Salazar A, Garc\u00eda-\u00c1lvarez T, Mazuecos-Blanca A (2020) IgA nephropathy after renal transplant: recurrences and de novo cases. Transplant Proc 52:515\u2013518","journal-title":"Transplant Proc"},{"key":"2149_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1744-9987.2012.01139.x","volume":"17","author":"K Sato","year":"2013","unstructured":"Sato K, Ishida H, Uchida K, Nitta K, Tanabe K (2013) Risk factors for recurrence of immunoglobulin a nephropathy after renal transplantation: single center study. Ther Apher Dial 17:213\u2013220","journal-title":"Ther Apher Dial"},{"key":"2149_CR23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/ki.2015.158","volume":"88","author":"L Berthelot","year":"2015","unstructured":"Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Dram\u00e9 M, Toupance O, Rieu P, Monteiro RC, Tour\u00e9 F (2015) Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 88:815\u2013822","journal-title":"Kidney Int"},{"key":"2149_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.23876\/j.krcp.20.183","volume":"40","author":"WY Park","year":"2021","unstructured":"Park WY, Kim Y, Paek JH, Jin K, Han S (2021) Clinical significance of serum galactose-deficient immunoglobulin A1 for detection of recurrent immunoglobulin A nephropathy in kidney transplant recipients. Kidney Res Clin Pract 40:317\u2013324","journal-title":"Kidney Res Clin Pract"},{"key":"2149_CR25","first-page":"309","volume":"9","author":"J Odum","year":"1994","unstructured":"Odum J, Peh CA, Clarkson AR, Bannister KM, Seymour AE, Gillis D, Thomas AC, Mathew TH, Woodroffe AJ (1994) Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 9:309\u2013312","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR26","doi-asserted-by":"publisher","first-page":"1277017","DOI":"10.3389\/fimmu.2023.1277017","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Tang Y, Lin T, Song T (2023) Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis. Front Immunol 14:1277017","journal-title":"Front Immunol"},{"key":"2149_CR27","first-page":"364","volume":"23","author":"J Bai","year":"2023","unstructured":"Bai J, Wu Q, Chen J, Zheng Z, Chang J, Wang L, Zhou Y, Guo Q (2023) Risk factors for recurrent IgA nephropathy after renal transplantation: a meta-analysis. Biomol Biomed 23:364\u2013375","journal-title":"Biomol Biomed"},{"key":"2149_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/ctr.12389","volume":"28","author":"JR Von Visger","year":"2014","unstructured":"Von Visger JR, Gunay Y, Andreoni KA, Bhatt UY, Nori US, Pesavento TE, Elkhammas EA, Winters HA, Nadasdy T, Singh N (2014) The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression. Clin Transplant 28:845\u2013854","journal-title":"Clin Transplant"},{"key":"2149_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13207","volume":"32","author":"MC Di Vico","year":"2018","unstructured":"Di Vico MC, Messina M, Fop F, Barreca A, Segoloni GP, Biancone L (2018) Recurrent IgA nephropathy after renal transplantation and steroid withdrawal. Clin Transplant 32:e13207","journal-title":"Clin Transplant"},{"key":"2149_CR30","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.transproceed.2016.08.011","volume":"48","author":"S Nijim","year":"2016","unstructured":"Nijim S, Vujjini V, Alasfar S, Luo X, Orandi B, Delp C, Desai NM, Montgomery RA, Lonze BE, Alachkar N (2016) Recurrent IgA nephropathy after kidney transplantation. Transplant Proc 48:2689\u20132694","journal-title":"Transplant Proc"},{"key":"2149_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/tri.13075","volume":"31","author":"N Leeaphorn","year":"2018","unstructured":"Leeaphorn N, Garg N, Khankin EV, Cardarelli F, Pavlakis M (2018) Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS\/OPTN database. Transpl Int 31:175\u2013186","journal-title":"Transpl Int"},{"key":"2149_CR32","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/j.1600-6143.2011.03667.x","volume":"11","author":"P Clayton","year":"2011","unstructured":"Clayton P, McDonald S, Chadban S (2011) Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 11:1645\u20131649","journal-title":"Am J Transplant"},{"key":"2149_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00007890-200101270-00011","volume":"71","author":"YS Kim","year":"2001","unstructured":"Kim YS, Moon JI, Jeong HJ, Kim MS, Kim SI, Choi KH, Lee HY, Han DS, Park K (2001) Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 71:233\u2013238","journal-title":"Transplantation"},{"key":"2149_CR34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S0140-6736(05)60198-5","volume":"349","author":"R Nowack","year":"1997","unstructured":"Nowack R, Birck R, van der Woude FJ (1997) Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349:774","journal-title":"Lancet"},{"key":"2149_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/ndt\/14.1.58","volume":"14","author":"IA Hauser","year":"1999","unstructured":"Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M (1999) Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58\u201363","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR36","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/ndt\/gfh773","volume":"20","author":"A Chandrakantan","year":"2005","unstructured":"Chandrakantan A, Ratanapanichkich P, Said M, Barker CV, Julian BA (2005) Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant 20:1214\u20131221","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1046\/j.1600-6143.2003.00294.x","volume":"4","author":"A Vongwiwatana","year":"2004","unstructured":"Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF (2004) Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 4:124\u2013129","journal-title":"Am J Transplant"},{"key":"2149_CR38","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3389\/fimmu.2019.01944","volume":"10","author":"WH Lim","year":"2019","unstructured":"Lim WH, Shingde M, Wong G (2019) Recurrent and de novo glomerulonephritis after kidney transplantation. Front Immunol 10:1944","journal-title":"Front Immunol"},{"key":"2149_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/08860220802134516","volume":"30","author":"Z Tang","year":"2008","unstructured":"Tang Z, Ji S-M, Chen D-R, Wen J-Q, Chen J-S, Liu Z-H, Li L-S (2008) Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation. Ren Fail 30:611\u2013616","journal-title":"Ren Fail"},{"key":"2149_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","volume":"23","author":"H Suzuki","year":"2019","unstructured":"Suzuki H (2019) Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol 23:26\u201331","journal-title":"Clin Exp Nephrol"},{"key":"2149_CR41","doi-asserted-by":"publisher","first-page":"1461879","DOI":"10.3389\/fmed.2024.1461879","volume":"11","author":"J Barratt","year":"2024","unstructured":"Barratt J, Lafayette RA, Floege J (2024) Therapy of IgA nephropathy: time for a paradigm change. Front Med (Lausanne) 11:1461879","journal-title":"Front Med (Lausanne)"},{"key":"2149_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.ajkd.2023.08.007","volume":"83","author":"DJ Caster","year":"2024","unstructured":"Caster DJ, Lafayette RA (2024) The treatment of primary IgA nephropathy: change, change, change. Am J Kidney Dis 83:229\u2013240","journal-title":"Am J Kidney Dis"},{"key":"2149_CR43","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","volume":"38","author":"PJ Gleeson","year":"2023","unstructured":"Gleeson PJ, O\u2019Shaughnessy MM, Barratt J (2023) IgA nephropathy in adults-treatment standard. Nephrol Dial Transplant 38:2464\u20132473","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR44","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.2174\/0929867329666220825121304","volume":"30","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Pella E, Kanbay M, Papagianni A (2023) SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease. Curr Med Chem 30:2039\u20132060","journal-title":"Curr Med Chem"},{"key":"2149_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","volume":"105","author":"H Zhang","year":"2024","unstructured":"Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J (2024) Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 105:189\u2013199","journal-title":"Kidney Int"},{"key":"2149_CR46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","volume":"19","author":"J Barratt","year":"2024","unstructured":"Barratt J, Liew A, Yeo SC, Fernstrom A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D, Cemdisiran Phase 2 Study I Collaborators (2024) Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial. Clin J Am Soc Nephrol 19:452\u2013462","journal-title":"Clin J Am Soc Nephrol"},{"key":"2149_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.444","author":"HBJ Trimarchi","year":"2024","unstructured":"Trimarchi HBJ, Heerspink H, Inker L, Bruchfeld A, Zhang H, Carroll K, Suzuki Y, Marsala J, Schneider B, Kateifides A, Rice K, Garlo K, Lafayette R (2024) A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfae069.444","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402:859\u2013870","journal-title":"Lancet"},{"key":"2149_CR49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH (2023) Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103:391\u2013402","journal-title":"Kidney Int"},{"key":"2149_CR50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/diagnostics14050512","volume":"14","author":"C Keskinis","year":"2024","unstructured":"Keskinis C, Moysidou E, Christodoulou M, Pateinakis P, Stangou M (2024) Diagnosing and treating IgAN: steroids, budesonide, or maybe both? Diagnostics (Basel) 14:512","journal-title":"Diagnostics (Basel)"},{"key":"2149_CR51","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.3390\/jcm12216927","volume":"12","author":"M Mathur","year":"2023","unstructured":"Mathur M, Chan TM, Oh KH, Kooienga L, Zhuo M, Pinto CS, Chacko B (2023) A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence. J Clin Med 12:6927","journal-title":"J Clin Med"},{"key":"2149_CR52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/ndt\/15.5.689","volume":"15","author":"K Oka","year":"2000","unstructured":"Oka K, Imai E, Moriyama T, Akagi Y, Ando A, Hori M, Okuyama A, Toki K, Kyo M, Kokado Y, Takahara S (2000) A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 15:689\u2013695","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR53","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1093\/ndt\/gfl506","volume":"21","author":"AE Courtney","year":"2006","unstructured":"Courtney AE, McNamee PT, Nelson WE, Maxwell AP (2006) Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 21:3550\u20133554","journal-title":"Nephrol Dial Transplant"},{"key":"2149_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.12659\/AOT.907167","volume":"23","author":"DB Cordeiro Cabral","year":"2018","unstructured":"Cordeiro Cabral DB, de Sandes-Freitas TV, Medina-Pestana JO, Mastroianni-Kirsztajn G (2018) Clinical features, treatment and prognostic factors of post-transplant immunoglobulin A nephropathy. Ann Transplant 23:166\u2013175","journal-title":"Ann Transplant"},{"key":"2149_CR55","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40620-016-0314-5","volume":"29","author":"M Messina","year":"2016","unstructured":"Messina M, di Vico MC, Ariaudo C, Mazzucco G, Fop F, Segoloni GP, Biancone L (2016) Treatment protocol with pulse and oral steroids for IgA nephropathy after kidney transplantation. J Nephrol 29:575\u2013583","journal-title":"J Nephrol"},{"key":"2149_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s13730-018-0341-2","volume":"7","author":"G Zagkotsis","year":"2018","unstructured":"Zagkotsis G, Vourlakou C, Paraskevopoulos A, Apostolou T (2018) Recurrence of crescentic IgA nephropathy after renal transplantation. CEN Case Rep 7:268\u2013273","journal-title":"CEN Case Rep"},{"key":"2149_CR57","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/nep.12151","volume":"18","author":"K Hotta","year":"2013","unstructured":"Hotta K, Fukasawa Y, Akimoto M, Tanabe T, Sasaki H, Fukuzawa N, Seki T, Togashi M, Harada H (2013) Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation. Nephrology (Carlton) 18:808\u2013812","journal-title":"Nephrology (Carlton)"},{"key":"2149_CR58","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/TP.0b013e3181b75374","volume":"88","author":"T Kennoki","year":"2009","unstructured":"Kennoki T, Ishida H, Yamaguchi Y, Tanabe K (2009) Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation 88:935\u2013941","journal-title":"Transplantation"},{"key":"2149_CR59","unstructured":"https:\/\/kdigo.org\/kdigo-2024-igan-igan-guideline-draft-available-for-public-review\/."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02149-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02149-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02149-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:58:59Z","timestamp":1777564739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/4\/1143\/8457118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02149-6","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JB\u00a0is a consultant to Calliditas Therapeutics AB and reports grants and consultancy and personal fees from Calliditas Therapeutics, Everest Medicines, and STADA Arzneimittel AG. Other authors have anything to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}